Abstract
Ischemia and the metabolic disorder it entails would seem to be the pathogenic mechanism behind acute cochlear deafness, irrespective of the triggering process. The prognosis is entirely dependent on the rapid initiation of an effective treatment. At the end of a double-blind therapeutic trial comparing Ginkgo biloba extract and a standard alpha blocker (nicergoline), a significant recovery was observed in both therapeutic groups, but improvement was distinctly better in the Ginkgo biloba group.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Audiometry, Pure-Tone
-
Audiometry, Speech
-
Clinical Trials as Topic
-
Cochlea / blood supply
-
Ergolines / therapeutic use*
-
Hearing Loss / drug therapy*
-
Hearing Loss, Conductive / drug therapy*
-
Humans
-
Ischemia / etiology
-
Middle Aged
-
Nicergoline / therapeutic use*
-
Plant Extracts / therapeutic use
-
Plants, Medicinal*
-
Random Allocation
-
Trees*
Substances
-
Ergolines
-
Plant Extracts
-
Nicergoline